Comparative Pharmacology
Head-to-head clinical analysis: ASPARLAS versus SYNRIBO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPARLAS versus SYNRIBO.
ASPARLAS vs SYNRIBO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asparaginase (ASPARLAS) hydrolyzes L-asparagine to L-aspartic acid and ammonia, depleting circulating asparagine. Leukemic cells with low asparagine synthetase activity rely on exogenous asparagine; depletion inhibits protein and nucleic acid synthesis, leading to cell death.
Omacetaxine mepesuccinate inhibits protein synthesis by binding to the ribosomal A-site and preventing aminoacyl-tRNA binding, thereby inhibiting peptide elongation. It also induces apoptosis in leukemic cells.
Intravenous (IV) or intramuscular (IM) injection: 2,500 IU/m² every 14 days as a component of multi-agent chemotherapy. Administer IV over 1-2 hours in 100 mL of 0.9% sodium chloride.
1.25 mg/m2 subcutaneously twice daily for 14 consecutive days, followed by 7 days rest (21-day cycle).
None Documented
None Documented
The terminal elimination half-life is approximately 25.7 days (range 17.8–33.6 days) in children and 22.0 days in adults, allowing for dosing every 2 weeks instead of 3 times per week as with native E. coli asparaginase.
Terminal half-life approximately 9.3 ± 7.0 hours; clinical context: once-daily subcutaneous dosing maintains steady-state concentrations.
Calaspargase pegol (ASPARLAS) is eliminated via the reticuloendothelial system; renal excretion is negligible (<2% unchanged), and biliary/fecal excretion has not been quantified. The pegylated asparaginase is cleared through proteolytic degradation.
Primarily fecal (80%) and renal (20%) as unchanged drug, with negligible metabolism.
Category C
Category C
Antineoplastic, Enzyme
Antineoplastic